Cardiff Oncology Files Definitive Proxy Statement

TL;DR

CRDF filed its proxy statement, standard procedure for shareholder meeting. No fee paid.

AI Summary

Cardiff Oncology, Inc. (CRDF) is filing a Definitive Proxy Statement (DEFA14A) on June 17, 2024, to solicit proxies for its upcoming annual meeting. The filing indicates no fee was required for this submission, suggesting it's a standard procedural document rather than a response to a specific event like a merger or significant financial transaction.

Why It Matters

This filing is a routine procedural document required for public companies to hold shareholder meetings and vote on corporate matters, ensuring transparency and shareholder participation in governance.

Risk Assessment

Risk Level: low — This is a routine DEFA14A filing, which is a standard procedural document for public companies and does not inherently carry significant financial risk.

Key Players & Entities

• Cardiff Oncology, Inc. (company) — Registrant
• 0001104659-24-071955 (filing_id) — Accession Number
• 20240617 (date) — Filing Date
• DEFA14A (document_type) — Form Type

FAQ

Key Financial Figures

• $3.51 — e of May 30, 2024, an exercise price of $3.51 per share and expire on March 7, 2034.

Filing Documents

• tm2417285d1_defa14a.htm (DEFA14A) — 12KB
• 0001104659-24-071955.txt ( ) — 13KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 Cardiff Oncology, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. Cardiff Oncology, Inc. Supplement to the Proxy Statement For the Annual Meeting of Stockholders To be Held on June 20, 2024 This proxy statement supplement, dated June 17, 2024 (the “Supplement”), supplements the definitive proxy statement (which we refer to as the “Proxy Statement”) of the Board of Directors of Cardiff Oncology, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission on April 25, 2024 relating to the annual meeting of stockholders of the Company to be held on Thursday, June 20, 2024 at 9:00 a.m., local time, at the Company's offices located at 11055 Flintkote Ave., San Diego, CA 92121. The purpose of this Supplement is to provide additional information with respect to Proposal 3 in the Proxy Statement. Except as described in this Supplement, the information disclosed in the Proxy Statement continues to apply. To the extent that information in this Supplement differs from information disclosed in the proxy statement, the information in this Supplement applies. As previously disclosed on June 3, 2024, the Board of Directors of the Company adopted resolutions to rescind stock options exercisable for an aggregate 1,697,712 shares of common stock that were granted on March 7, 2024 that were made in reliance on the 2022 amendment to the 2021 Equity Incentive Plan and approved replacement grants with terms identical to the stock options rescinded. The replacement grants will be effective only upon stockholder approval of Proposal 3. We describe in the following table the replacement grants which have been granted and will be effective only upon stockholder approval of Proposal 3. Name and Position Options Mark Erlander, CEO 510,000 James Levine, CFO 205,008 Fairooz Kabbinavar, CMO 205,008 Tod Smeal, CSO 205,008 Employees 572,688 All of the options granted have a grant date of May 30, 2024, an exercise price of $3.51 per share and expire on March 7, 2034. 25% of the options granted vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installment thereafter, subject to the continued service of the option holder. Any proxies submitted by stockholders before the date of this Supplement will be voted as instructed on those proxies, unless a stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the Proxy Statement regarding how to submit proxies or vote at the Annual Meeting. - 2 -

View Full Filing

View this DEFA14A filing on SEC EDGAR